Pub Date : 2022-04-30DOI: 10.33978/2307-3586-2022-18-14-36-41
D. Bordin, I. Voynovan
The results of a clinical study of the efficacy and safety of taking a dietary supplement Gastrokur in combination with pantoprazole in patients with Helicobacter pylori are presented. Material and methods. 10 patients with H. pylori infection confirmed according to 13C-urease respiratory test for four weeks received the dietary supplement Gastrokur two capsules three times a day in combination with pantoprazole 40 mg once a day. A special condition was the compliance with Gastrokur temperature regime of storage from +40 to +100 С. The efficacy of eradication was evaluated using a 13C urease breath test 30 days after completion of treatment. Results. H. pylori eradication was achieved in two out of 10 (20%) patients according to the ITT criterion and in two out of nine (22.2%) patients according to the PP criterion. By the 14th day of therapy, 80% of patients had completely stopped symptoms of dyspepsia with the effect remaining for a month after the end of therapy. During the first two weeks of therapy, three patients had bloating, five had mushy stools no more than three times a day. These phenomena were not pronounced and did not require interruption of treatment. One patient dropped out of the study due to an exacerbation of pink lichen on the 21st day of therapy, which independently passed two days after discontinuation of treatment. Conclusion. A course of therapy with a biologically active food supplement Gastrokur in combination with pantoprazole led to the eradication of H. pylori in 20%. Against the background of therapy, a good positive clinical dynamics was observed. No serious adverse events have been reported, with the exception of an exacerbation of pink lichen in one patient.
{"title":"Efficacy and Safety Evaluation of Gastrokur Dietary Supplement in Combination with Pantoprazole in Patients with Helicobacter pylori","authors":"D. Bordin, I. Voynovan","doi":"10.33978/2307-3586-2022-18-14-36-41","DOIUrl":"https://doi.org/10.33978/2307-3586-2022-18-14-36-41","url":null,"abstract":"The results of a clinical study of the efficacy and safety of taking a dietary supplement Gastrokur in combination with pantoprazole in patients with Helicobacter pylori are presented. Material and methods. 10 patients with H. pylori infection confirmed according to 13C-urease respiratory test for four weeks received the dietary supplement Gastrokur two capsules three times a day in combination with pantoprazole 40 mg once a day. A special condition was the compliance with Gastrokur temperature regime of storage from +40 to +100 С. The efficacy of eradication was evaluated using a 13C urease breath test 30 days after completion of treatment. Results. H. pylori eradication was achieved in two out of 10 (20%) patients according to the ITT criterion and in two out of nine (22.2%) patients according to the PP criterion. By the 14th day of therapy, 80% of patients had completely stopped symptoms of dyspepsia with the effect remaining for a month after the end of therapy. During the first two weeks of therapy, three patients had bloating, five had mushy stools no more than three times a day. These phenomena were not pronounced and did not require interruption of treatment. One patient dropped out of the study due to an exacerbation of pink lichen on the 21st day of therapy, which independently passed two days after discontinuation of treatment. Conclusion. A course of therapy with a biologically active food supplement Gastrokur in combination with pantoprazole led to the eradication of H. pylori in 20%. Against the background of therapy, a good positive clinical dynamics was observed. No serious adverse events have been reported, with the exception of an exacerbation of pink lichen in one patient.","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83522451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-30DOI: 10.33978/2307-3586-2022-18-14-66-69
E. A. Kondrashova, N. Belostotsky, A. Strachuk, E. Baulo, A. Parfenov
A decrease in the activity of disaccharidases in the duodenal mucosa made it possible to establish in patient K. enteropathy with impaired membrane digestion (EIMD). An increase in the activity of disaccharidases in the distal ileum during EIMD is a verification of the formation of a compensatory reaction according to the type of proximodistal gradients. Treatment with the cytoprotector rebamipide for 12 weeks increases the enzymatic activity of the small intestine in EIMD.
{"title":"Successful Diagnosтic and Treatment of Enteropathy with Impaired Membrane Digestion by FODMAP-diet and Rebamipid","authors":"E. A. Kondrashova, N. Belostotsky, A. Strachuk, E. Baulo, A. Parfenov","doi":"10.33978/2307-3586-2022-18-14-66-69","DOIUrl":"https://doi.org/10.33978/2307-3586-2022-18-14-66-69","url":null,"abstract":"A decrease in the activity of disaccharidases in the duodenal mucosa made it possible to establish in patient K. enteropathy with impaired membrane digestion (EIMD). An increase in the activity of disaccharidases in the distal ileum during EIMD is a verification of the formation of a compensatory reaction according to the type of proximodistal gradients. Treatment with the cytoprotector rebamipide for 12 weeks increases the enzymatic activity of the small intestine in EIMD.","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"72 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87715571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-30DOI: 10.33978/2307-3586-2022-18-14-54-57
A. O. Buyeverov, K.M. Roschina, O. Kuzmina, P. Bogomolov
We present clinical case of patient with initially diagnosed chronic hepatitis C with an autoimmune component corresponding to type 1 autoimmune hepatitis. Considering that at the time of diagnosis, the therapeutic possibilities of hepatitis C were limited to the use of standard or pegylated interferon α in combination with ribavirin, in order to avoid the adverse immunomodulatory effect of interferon, we previously suppressed the autoimmune component with immunosuppressors. After 6-month course of prednisolone and azathioprine, antiviral therapy with interferon α and ribavirin was carried out with the achievement of sustained virological and biochemical response. After 7 years of complete virological, immunological and biochemical remission, the patient manifested autoimmune hepatitis type 2. The appointment of prednisolone and azathioprine led to a stable drug-induced remission.
{"title":"Cross-syndrome of Chronic Hepatitis C and Type 1 Autoimmune Hepatitis with Subsequent Transformation into Type 2 Autoimmune Hepatitis: a Clinical Case","authors":"A. O. Buyeverov, K.M. Roschina, O. Kuzmina, P. Bogomolov","doi":"10.33978/2307-3586-2022-18-14-54-57","DOIUrl":"https://doi.org/10.33978/2307-3586-2022-18-14-54-57","url":null,"abstract":"We present clinical case of patient with initially diagnosed chronic hepatitis C with an autoimmune component corresponding to type 1 autoimmune hepatitis. Considering that at the time of diagnosis, the therapeutic possibilities of hepatitis C were limited to the use of standard or pegylated interferon α in combination with ribavirin, in order to avoid the adverse immunomodulatory effect of interferon, we previously suppressed the autoimmune component with immunosuppressors. After 6-month course of prednisolone and azathioprine, antiviral therapy with interferon α and ribavirin was carried out with the achievement of sustained virological and biochemical response. After 7 years of complete virological, immunological and biochemical remission, the patient manifested autoimmune hepatitis type 2. The appointment of prednisolone and azathioprine led to a stable drug-induced remission.","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"45 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87344973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-30DOI: 10.33978/2307-3586-2022-18-14-18-23
S. Bykova, E. Sabelnikova, O. Akhmadullina, A. Novikov, N. Belostotsky, E. Baulo, S. Dbar, A. Parfenov
Celiac disease is a classic autoimmune disease that triggers enterocyte damage and villous atrophy of the small intestine mucosa in genetically determined individuals in response to gluten-containing foods. Damage to the ultrastructure of epithelial cell membranes causes breakdown of the digestive transport conveyor, which disrupts the most important stage of the digestive transport conveyor – membrane digestion, which plays an important role in the final assimilation of nutrients. There is evidence of a correlation between the activity of intestinal carbohydrases and the degree of atrophy of the mucosa villi, which suggests that the activity of disaccharidases can serve as an indicator of the functional recovery of TTS in celiac disease. Objective: to assess the activity of intestinal carbohydrases in patients with celiac disease, depending on adherence to GFD. Materials and methods. We examined 109 patients with celiac disease, the diagnostic criterion for which was a combination of clinical symptoms, serological tests and histological data. The median age of the examined patients was 41.5 years (Q1–Q3: 30–55 years, Shapiro p-value < 0.01). There were 16 men (14.7%), median age 30; women – 93 (85.3%), median age 44 years. Depending on adherence to GFD, patients with celiac disease were divided into 3 groups: Group I – 39 patients with newly diagnosed celiac disease, Group II – 28 patients who consciously or unconsciously violated GFD, Group III – 42 patients who observed GFD from 6 months up to 15 years. The control group consisted of 30 practically healthy people comparable in age and sex. Their average age was 33.9 years (Q1–Q3: 24–35). All patients underwent esophagogastroduodenoscopy with a morphological and biochemical study of the mucosal tissue with a study of the activity of intestinal carbohydrases according to the method of A. Dalkvist modified by N.I. Belostotsky. The activity of disaccharidases of the small intestine mucosa was expressed in nanograms of glucose per milligram of tissue per minute (ng glucose/mg tissue × min). Results. In patients with newly diagnosed celiac disease, a decrease in the activity of glucoamylase glucoamylase (84.6%), maltase (87.2%) and sucrase (82.05%) (p < 0.01) is significantly more often detected compared to group III (glucoamylase – 33.3%; maltase – 45.2%; sucrase – 45.2%). Deficiency of all carbohydrases (glucoamylase, maltase, sucrase and lactase) was detected in 61.5% of patients. When comparing the indicators of carbohydrase activity in the groups of patients examined by us, it turned out that the average level of activity of glucoamylase, sucrase and maltase increased significantly more often as AGD was observed, however, their average values remained below the control level, which was less related to maltase. Thus, in group III, the level of maltase was 860 (644.5; 1413.5), and in the control group – 887.0 (854.5; 1146), which indicates a high ability of maltase to recover with strict adherenc
{"title":"The Activity of Intestinal Carbohydrases in Patients with Celiac Disease, Depending on Adherence to the Gluten-free Diet","authors":"S. Bykova, E. Sabelnikova, O. Akhmadullina, A. Novikov, N. Belostotsky, E. Baulo, S. Dbar, A. Parfenov","doi":"10.33978/2307-3586-2022-18-14-18-23","DOIUrl":"https://doi.org/10.33978/2307-3586-2022-18-14-18-23","url":null,"abstract":"Celiac disease is a classic autoimmune disease that triggers enterocyte damage and villous atrophy of the small intestine mucosa in genetically determined individuals in response to gluten-containing foods. Damage to the ultrastructure of epithelial cell membranes causes breakdown of the digestive transport conveyor, which disrupts the most important stage of the digestive transport conveyor – membrane digestion, which plays an important role in the final assimilation of nutrients. There is evidence of a correlation between the activity of intestinal carbohydrases and the degree of atrophy of the mucosa villi, which suggests that the activity of disaccharidases can serve as an indicator of the functional recovery of TTS in celiac disease. Objective: to assess the activity of intestinal carbohydrases in patients with celiac disease, depending on adherence to GFD. Materials and methods. We examined 109 patients with celiac disease, the diagnostic criterion for which was a combination of clinical symptoms, serological tests and histological data. The median age of the examined patients was 41.5 years (Q1–Q3: 30–55 years, Shapiro p-value < 0.01). There were 16 men (14.7%), median age 30; women – 93 (85.3%), median age 44 years. Depending on adherence to GFD, patients with celiac disease were divided into 3 groups: Group I – 39 patients with newly diagnosed celiac disease, Group II – 28 patients who consciously or unconsciously violated GFD, Group III – 42 patients who observed GFD from 6 months up to 15 years. The control group consisted of 30 practically healthy people comparable in age and sex. Their average age was 33.9 years (Q1–Q3: 24–35). All patients underwent esophagogastroduodenoscopy with a morphological and biochemical study of the mucosal tissue with a study of the activity of intestinal carbohydrases according to the method of A. Dalkvist modified by N.I. Belostotsky. The activity of disaccharidases of the small intestine mucosa was expressed in nanograms of glucose per milligram of tissue per minute (ng glucose/mg tissue × min). Results. In patients with newly diagnosed celiac disease, a decrease in the activity of glucoamylase glucoamylase (84.6%), maltase (87.2%) and sucrase (82.05%) (p < 0.01) is significantly more often detected compared to group III (glucoamylase – 33.3%; maltase – 45.2%; sucrase – 45.2%). Deficiency of all carbohydrases (glucoamylase, maltase, sucrase and lactase) was detected in 61.5% of patients. When comparing the indicators of carbohydrase activity in the groups of patients examined by us, it turned out that the average level of activity of glucoamylase, sucrase and maltase increased significantly more often as AGD was observed, however, their average values remained below the control level, which was less related to maltase. Thus, in group III, the level of maltase was 860 (644.5; 1413.5), and in the control group – 887.0 (854.5; 1146), which indicates a high ability of maltase to recover with strict adherenc","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78264607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-30DOI: 10.33978/2307-3586-2022-18-14-58-64
N. Fadeeva, G.B. Artykova, A.Yu. Filimonov, D.S. Filina, N. Vidyaeva, S. Chudnykh, O. Knyazev, S. G. Khomeriki, K. Nikolskaya, D. Bordin, A. Parfenov
The clinical case of a complicated course of Crohn's disease (CD) in an elderly patient is presented. The article reflects thefeatures of the diagnosis, tactics of conservative and surgical treatment of CD. Timely diagnosis of colorectal cancer (CRC) in an elderly patient with CD also demonstrated.
{"title":"Clinical Case of Complicated Course of Crohn’s Disease in an Elderly Patient","authors":"N. Fadeeva, G.B. Artykova, A.Yu. Filimonov, D.S. Filina, N. Vidyaeva, S. Chudnykh, O. Knyazev, S. G. Khomeriki, K. Nikolskaya, D. Bordin, A. Parfenov","doi":"10.33978/2307-3586-2022-18-14-58-64","DOIUrl":"https://doi.org/10.33978/2307-3586-2022-18-14-58-64","url":null,"abstract":"The clinical case of a complicated course of Crohn's disease (CD) in an elderly patient is presented. The article reflects thefeatures of the diagnosis, tactics of conservative and surgical treatment of CD. Timely diagnosis of colorectal cancer (CRC) in an elderly patient with CD also demonstrated.","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80860952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-30DOI: 10.33978/2307-3586-2022-18-14-24-27
V. I. Mordasova, D. V. Kopylova, I. Podstavkina, E. N. Ponomareva, I. Timchenko
A feature of COVID-19 is the high frequency of gastroenterological symptoms caused by the defeat of the digestive organs by the SARS-CoV-2 coronavirus, as well as the exacerbation of chronic gastroenterological pathology against the background of infection and its aggressive therapy. Unfortunately, COVID-19 has a significant impact on the course and outcome of diverticular colon disease. The article presents the variants and frequency of exacerbation of diverticular disease against the background of viral infection.
{"title":"Gastrointestinal Tract in Captivity at COVID-19: the Impact of a New Coronavirus Infection on the Course and Outcome of Diverticular Colon Disease","authors":"V. I. Mordasova, D. V. Kopylova, I. Podstavkina, E. N. Ponomareva, I. Timchenko","doi":"10.33978/2307-3586-2022-18-14-24-27","DOIUrl":"https://doi.org/10.33978/2307-3586-2022-18-14-24-27","url":null,"abstract":"A feature of COVID-19 is the high frequency of gastroenterological symptoms caused by the defeat of the digestive organs by the SARS-CoV-2 coronavirus, as well as the exacerbation of chronic gastroenterological pathology against the background of infection and its aggressive therapy. Unfortunately, COVID-19 has a significant impact on the course and outcome of diverticular colon disease. The article presents the variants and frequency of exacerbation of diverticular disease against the background of viral infection.","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"73 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89538907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-25DOI: 10.33978/2307-3586-2022-18-13-34-37
Yu.V. Batukhtina, R. Zukov
The article presents a clinical case of treatment of orbital B-cell lymphoma of the extranodal marginal zone. This case report demonstrates the safety and efficacy of ibrutinib monotherapy in patients with relapsed/refractory LMZ previously reported in the PCYC-1121 study. Research and clinical evidence support the use of ibrutinib monotherapy as an alternative to chemotherapy in this patient population with a favorable benefit-risk profile and a convenient once-daily regimen.
{"title":"Monotherapy with Ibrutinib in B-cell Lymphoma of the Extranodal Marginal Zone","authors":"Yu.V. Batukhtina, R. Zukov","doi":"10.33978/2307-3586-2022-18-13-34-37","DOIUrl":"https://doi.org/10.33978/2307-3586-2022-18-13-34-37","url":null,"abstract":"The article presents a clinical case of treatment of orbital B-cell lymphoma of the extranodal marginal zone. This case report demonstrates the safety and efficacy of ibrutinib monotherapy in patients with relapsed/refractory LMZ previously reported in the PCYC-1121 study. Research and clinical evidence support the use of ibrutinib monotherapy as an alternative to chemotherapy in this patient population with a favorable benefit-risk profile and a convenient once-daily regimen.","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82281562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-25DOI: 10.33978/2307-3586-2022-18-13-30-33
R. Zukov, Yu.V. Batukhtina, V. A. Khorzhevsky
The article presents a clinical case of treatment of indolent non-Hodgkin's lymphoma (follicular lymphoma) stage IV at a young age with a relapsing course of the disease with a partial response and no tumor transformation. The prospects for the treatment of follicular lymphoma at the moment are very interesting and quite encouraging.
{"title":"Treatment of Follicular Lymphoma","authors":"R. Zukov, Yu.V. Batukhtina, V. A. Khorzhevsky","doi":"10.33978/2307-3586-2022-18-13-30-33","DOIUrl":"https://doi.org/10.33978/2307-3586-2022-18-13-30-33","url":null,"abstract":"The article presents a clinical case of treatment of indolent non-Hodgkin's lymphoma (follicular lymphoma) stage IV at a young age with a relapsing course of the disease with a partial response and no tumor transformation. The prospects for the treatment of follicular lymphoma at the moment are very interesting and quite encouraging.","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"67 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84044557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-25DOI: 10.33978/2307-3586-2022-18-13-6-10
R. Zukov, V. Vyazmin, N. Chanchikova
Relevance. Prostate cancer (PC) is one of the most common malignant neoplasms in men. Every year, about 1.4 million new cases of prostate cancer are diagnosed in the world and 366,000 men die each year from this pathology. Despite the presence of a fairly wide range of diagnostic options in the early diagnosis of prostate cancer, primarily the determination of the level of prostate specific antigen (PSA) in the blood serum and multiparametric magnetic resonance imaging (mpMRI), there remains a group of patients with ambiguous values of the above indicators. The use of positron emission tomography combined with computed tomography (PET/CT) with a tumoritropic radiopharmaceutical drug (RFLP) 18F-PSMA improves the early diagnosis of prostate cancer, which is the key to success for successful treatment, duration and quality of life of the patient. Material and methods. The study included 30 patients with suspected prostate cancer, based on the PSA level in the ʽgray zoneʼ 2–10 ng/ml and Pi-RADS 3 according to the MRI data. All patients underwent PET/CT with 18F-PSMA, with further morphological verification of the process. Results. Out of 30 patients, 7 (23.33%) had positive PET/CT with 18F-PSMA. The diagnostic model obtained during the construction and subsequent analysis of the SUV level ROC-curve showed high values of sensitivity (86%), specificity (100%), diagnostic accuracy (86%) and positive predictive value (100%) of the method (area under ROC-curve (AUC) 0.93), with reference indicators of RFLP accumulation – standardized uptake value (SUV) 2.5. The negative predictive value was 27%. Conclusion. Our study confirmed the high diagnostic accuracy of PET/CT with 18F-PSMA in the differential diagnosis of a tumor process in the prostate gland, with a reference indicator SUV > 2.5. We recommend 18F-PSMA PET/CT in patients with suspected PCa who have ambiguous PSA (2-10 ng/mL) and mpMRI (Pi-RADS 3) findings.
{"title":"Diagnostic Possibilities of PET/CT with 18F-PSMA in Patients with Suspected Prostate Cancer","authors":"R. Zukov, V. Vyazmin, N. Chanchikova","doi":"10.33978/2307-3586-2022-18-13-6-10","DOIUrl":"https://doi.org/10.33978/2307-3586-2022-18-13-6-10","url":null,"abstract":"Relevance. Prostate cancer (PC) is one of the most common malignant neoplasms in men. Every year, about 1.4 million new cases of prostate cancer are diagnosed in the world and 366,000 men die each year from this pathology. Despite the presence of a fairly wide range of diagnostic options in the early diagnosis of prostate cancer, primarily the determination of the level of prostate specific antigen (PSA) in the blood serum and multiparametric magnetic resonance imaging (mpMRI), there remains a group of patients with ambiguous values of the above indicators. The use of positron emission tomography combined with computed tomography (PET/CT) with a tumoritropic radiopharmaceutical drug (RFLP) 18F-PSMA improves the early diagnosis of prostate cancer, which is the key to success for successful treatment, duration and quality of life of the patient. Material and methods. The study included 30 patients with suspected prostate cancer, based on the PSA level in the ʽgray zoneʼ 2–10 ng/ml and Pi-RADS 3 according to the MRI data. All patients underwent PET/CT with 18F-PSMA, with further morphological verification of the process. Results. Out of 30 patients, 7 (23.33%) had positive PET/CT with 18F-PSMA. The diagnostic model obtained during the construction and subsequent analysis of the SUV level ROC-curve showed high values of sensitivity (86%), specificity (100%), diagnostic accuracy (86%) and positive predictive value (100%) of the method (area under ROC-curve (AUC) 0.93), with reference indicators of RFLP accumulation – standardized uptake value (SUV) 2.5. The negative predictive value was 27%. Conclusion. Our study confirmed the high diagnostic accuracy of PET/CT with 18F-PSMA in the differential diagnosis of a tumor process in the prostate gland, with a reference indicator SUV > 2.5. We recommend 18F-PSMA PET/CT in patients with suspected PCa who have ambiguous PSA (2-10 ng/mL) and mpMRI (Pi-RADS 3) findings.","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78535774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-25DOI: 10.33978/2307-3586-2022-18-13-24-28
D. M. Ponomarenko, D. Yukalchuk, S. S. Sidorova, Yulia A Chapygina
Using an example from clinical practice, the issues of treatment of advanced non-small cell lung cancer in the absence of activating mutations are considered.
利用临床实践中的一个例子，在没有激活突变的情况下考虑晚期非小细胞肺癌的治疗问题。
{"title":"First-Line Double Immunotherapy for Non-Small Cell Advanced Lung Cancer","authors":"D. M. Ponomarenko, D. Yukalchuk, S. S. Sidorova, Yulia A Chapygina","doi":"10.33978/2307-3586-2022-18-13-24-28","DOIUrl":"https://doi.org/10.33978/2307-3586-2022-18-13-24-28","url":null,"abstract":"Using an example from clinical practice, the issues of treatment of advanced non-small cell lung cancer in the absence of activating mutations are considered.","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86716722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：